received by the International Bureau on 26.Nov.2017 (26.1 1.2017

1. A method for delivering nucleic acid sequences into a subject-animal's cells, wherein a subject-animal is either, a human, or a non- human animal modified to have one or more human immune system vulnerabilities, the method comprising: a. administering to the subject-animal a plurality of immune system modulators comprising: i. a tumor necrosis factor alpha (TNFa) inhibitor; ii. a nuclear factor κΒ (NFKB) inhibitor; iii. an interferon regulatory factor 3 (IRF3) inhibitor; and iv. a toll-like receptor 9 (TLR9) inhibitor; b. delivering said nucleic acid sequences into said subject-animal's cells; c. wherein said delivering step occurs after said administering step; and d. wherein said nucleic acid sequences are delivered using a nucleic acid delivery vehicle (NADV); and

13

e. wherein the dose of NADV is 10 NADV particles or more.

2. The method of claim 1 further comprising the step of administering a mechanistic target of rapamycin (mTOR) inhibitor and wherein said delivering step occurs after each said administering step.

3. The method of claim 2, wherein the mTOR inhibitor is selected from the group consisting of rapamycin, temsirolimus, everolimus, and deforolimus.

4. The method of claim 1 further comprising the step of administering a selective serotonin reuptake inhibitor (SSRI) and wherein said delivering step occurs after each said administering step.

5. The method of claim 4, wherein the SSRI is selected from the group consisting of

citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, dapoxetine, indalpine, zimelidine, cericlamine, and panuramine.

6. The method of claim 1 further comprising the step of administering a serotonin- norepinephrine reuptake inhibitor (SNRI) and wherein said delivering step occurs after each said administering step.

7. The method of claim 6, wherein the SNRI is selected from the group consisting of

venlafaxine, sibutramine, duloxetine, atomoxetine, desvenlafaxine, milnacipran, and levomilnacipran.

8. The method of claim 1, wherein the TNFa inhibitor is selected from the group consisting of adalimumab, etanercept, infliximab, or 2,5-Dimethoxy-4-iodoamphetamine.

9. The method of claim 1 , wherein the NFKB inhibitor s selected from the group consisting of ectinascidin 743, digitoxin, ouabain, bortezomib, chromomycin A3, emetine, fluorosalan, narasin, lestaurtinib, tribromsalam, bithionol, and daunorubicinum.

10. The method of claim 1, wherein the IRF3 inhibitor is selected from the group consisting of sertraline, trifluoperazine, or fluphenazine.

11. The method of claim 1 , wherein the TLR9 inhibitor is selected from the group consisting of 3 - [4-(6-(3 -(dimethy lamino)propoxy)benzo[d] oxazol-2-yl)phenoxy ] -N,N- dimethylpropan- 1 -amine, 6- [3 -(pyrrolidin- 1 -yl)propoxy)-2-(4-(3 -(pyrrolidin- 1 - yl)propoxy)phenyl]benzo[d]oxazole, or hydroxychloroquine.

12. The method of claim 1 wherein the NADV is a virus capsid.

13. The method of claim 1 wherein the NADV is a polyplex.

14. The method of claim 1 wherein the NADV is an enveloped polyplex.

15. The method of claim 1 wherein said delivering step occurs before said administering step.

16. The method of claim 1 wherein said delivering step occurs simultaneously with said

administering step.

17. The method of claim 1 wherein the nucleic acid sequence comprises a nucleic acid

sequence containing a nucleic acid sequence coding for clustered regularly interspaced short palindromic repeats (CRISPR) that is under the control of a tetracycline induced promoter.

18. The nucleic acid sequence of claim 17 further comprising cytosine-phosphate-guanine (CpG) oligodeoxynucleotides (CpG-ODN) nucleic acid sequences.

19. The nucleic acid sequence of claim 17 further comprising: a. one or more cis-acting hydrolase element (CHYSEL) sequences linking two or more gene sequences under the control of said tetracycline induced promoter; and b. wherein said two or more genes code for proteins.